Kyverna Therapeutics, Inc. income statement KYTX

Annual Quarterly

It recorded a net loss of $161.3 million. Diluted earnings per share were -$3.64.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

FY 2026
Jun 30, 2026
FY 2025
Dec 31, 2025
FY 2024
Dec 31, 2024
Research and development
115
-15.2%
134
+18.9%
112
Selling, general and administrative
44
+22.1%
36
+19.8%
30
Operating income
-159
+7.4%
-170
-19.1%
-143
Income tax
—
0
0
Net income
-153
+3.8%
-161
-26.5%
-127
Basic EPS
-2.89
+21.5%
-3.64
-9.3%
-3.33
Diluted EPS
-2.89
+21.5%
-3.64
-9.3%
-3.33
Weighted average shares, basic
53
+22.5%
44
+15.5%
38
Weighted average shares, diluted
53
+22.5%
44
+15.5%
38
Other measures
Depreciation and amortization
2
-26.6%
2
-15.7%
2
EBITDA
-157
+7.2%
-168
-19.6%
-140
Interest coverage
-88.69x
-347.29x
-1,004.25x
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
KYTX (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Emeryville, CA
SEC filer status
, Emerging growth company
SEC CIK
1994702
Former names
Kyverna Therapeutics, Inc. (until Oct 19, 2026)

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.